Melior Discovery scientific advisors

April 2009 Melior Discovery Newsletter

Other Articles:

In Vivo PK and Bioanalytical Capabilities

An effective drug must remain at the site of action long enough to have the desired pharmacological effect. Early evaluation of the ability of a compound to move from the dosing site to the target site is an essential step in drug development.

Melior offers a set of comprehensive in vivo rodent PK models, ranging from a rapid PK screening service to multi-group custom PK study designs that are integral to the interpretation of drug properties and the ability to relate these to optimum dosing paradigms.

Bioanalytical testing provides quantitative measurement of an active drug and/or its metabolites in biological matrices (plasma, brain tissue, urine etc.). Custom specific and sensitive bioanalytical methods are required to make these measurements. Melior’s bioanalytical lab employs state-of-the-art high-throughput LC/MS/MS equipment to offer the most sensitive bioanalytical method possible.

Our highly consultative approach to contract research has enabled our team to bring their expertise in strategy and protocol design to each client according to their specific needs.

All of Melior’s preclinical services are conducted in state-of-the-art laboratory facilities located in Exton, Pennsylvania, USA.

Other articles:
» Is There A Shortcut To Drug Development Success?
» Pioneering High Throughput Pharmacology as a Uniquely Productive Drug Discovery Strategy
» Melior Announces the Availability of an Exclusive Model for Alzheimer’s Disease

Back to top of page